Italy is Europe’s third largest pharmaceutical market, yet it ranks only ninth in the number of NIH-registered clinical trials per capita. The aim of our study was to explore stakeholders’ perception of Italy as place to undertake clinical trials, and to estimate the potential economic impact of selected reforms in terms of incremental trial activity.

Towards a more competitive Italy in clinical research: the survey of attitudes towards trial sites in Europe (the SAT-EU study™)

JOMMI, CLAUDIO;TARRICONE, ROSANNA;
2015

Abstract

Italy is Europe’s third largest pharmaceutical market, yet it ranks only ninth in the number of NIH-registered clinical trials per capita. The aim of our study was to explore stakeholders’ perception of Italy as place to undertake clinical trials, and to estimate the potential economic impact of selected reforms in terms of incremental trial activity.
2015
2015
Gehring, Marta; Jommi, Claudio; Tarricone, Rosanna; Cirenei, Mariapia; Ambrosio, Giuseppe
File in questo prodotto:
File Dimensione Formato  
EpidBioPubHealth2015.pdf

non disponibili

Descrizione: EpidemiologyBioPublicHealth2015
Tipologia: Pdf editoriale (Publisher's layout)
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 1.21 MB
Formato Adobe PDF
1.21 MB Adobe PDF   Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11565/3985659
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 6
social impact